Published in Int J Urol on October 14, 2010
Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression. J Pharmacol Exp Ther (2012) 0.88
Editorial comment to carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. Int J Urol (2010) 0.75
Carvedilol ameliorates early diabetic nephropathy in streptozotocin-induced diabetic rats. Biomed Res Int (2014) 0.75
Fetal Kidney Cells Can Ameliorate Ischemic Acute Renal Failure in Rats through Their Anti-Inflammatory, Anti-Apoptotic and Anti-Oxidative Effects. PLoS One (2015) 0.75
Medical perspective in testicular ischemia-reperfusion injury. Exp Ther Med (2017) 0.75
Antioxidants in experimental ischemia-reperfusion injury of the testis: Where are we heading towards? World J Methodol (2017) 0.75
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med (2013) 10.74
Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur Urol (2009) 2.03
Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. Int J Urol (2014) 2.02
A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother (2010) 1.70
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med (2010) 1.66
Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int (2012) 1.52
Effect of tamsulosin on bladder blood flow and bladder function in a rat model of bladder over distention/emptying induced bladder overactivity. J Urol (2011) 1.43
Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol (2010) 1.28
Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma. Eur J Cancer (2011) 1.26
Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1. Jpn J Clin Oncol (2010) 1.18
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial. Jpn J Clin Oncol (2013) 1.10
STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J Clin Oncol (2007) 1.06
Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther (2010) 1.04
Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol Dial Transplant (2005) 0.97
Kidney Cancer Working Group report. Jpn J Clin Oncol (2010) 0.97
Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother (2006) 0.97
Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther (2008) 0.94
Analysis of bone mineral density in urolithiasis patients. Int J Urol (2005) 0.92
Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int (2006) 0.89
Eviprostat suppresses urinary oxidative stress in a rabbit model of partial bladder outlet obstruction and in patients with benign prostatic hyperplasia. Phytother Res (2010) 0.88
Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int (2013) 0.87
Brain metastases from urachal carcinoma. J Clin Neurosci (2003) 0.87
STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma. Eur Urol (2012) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell Carcinoma. J Immunother (2015) 0.85
The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer (2004) 0.84
A malignant Leydig cell tumor of the testis. Int Urol Nephrol (2006) 0.84
Osteopontin knockdown in the kidneys of hyperoxaluric rats leads to reduction in renal calcium oxalate crystal deposition. Urolithiasis (2014) 0.84
Edaravone protects against ischemia/reperfusion-induced functional and biochemical changes in rat urinary bladder. Urology (2005) 0.83
Effects of chronic treatment with vardenafil, a phosphodiesterase 5 inhibitor, on female rat bladder in a partial bladder outlet obstruction model. BJU Int (2008) 0.83
Bladder outlet obstruction accelerates bladder carcinogenesis. BJU Int (2008) 0.82
Chronic treatment with a PDE5 inhibitor increases contractile force of normal bladder in rats. Int Urol Nephrol (2009) 0.82
[A case of prostatic cancer with a low PSA level accompanied with cystic formation requiring differentiation from adenocarcinoma of the seminal vesicle]. Hinyokika Kiyo (2012) 0.81
Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma. Int J Oncol (2003) 0.81
Induction of antigen specific cellular immunity by vaccination with peptides from MN/CA IX in renal cell carcinoma. Oncol Rep (2003) 0.81
Non-ischemic nephron-sparing surgery for small renal cell carcinoma: complete tumor enucleation using a microwave tissue coagulator. Jpn J Clin Oncol (2002) 0.81
Renal cell carcinoma-associated G250 methylation and expression: in vivo and in vitro studies. Urology (2002) 0.80
Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology (2009) 0.80
Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis. Int J Clin Oncol (2013) 0.79
[A case of primary transitional cell carcinoma of the prostate]. Hinyokika Kiyo (2003) 0.79
Efficacy of silodosin in patients undergoing brachytherapy: a randomized trial involving a pressure flow study. World J Urol (2014) 0.79
Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. Jpn J Clin Oncol (2013) 0.78
[Pulmonary metastasis of renal cell carcinoma 20 years after nephrectomy]. Hinyokika Kiyo (2006) 0.78
Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol (2013) 0.78
[Clinical study of acute urinary retention]. Nihon Hinyokika Gakkai Zasshi (2006) 0.78
Add-on anticholinergic therapy for residual nocturia in patients with lower urinary tract symptoms receiving α1-blocker treatment: a multi-centre, prospective, randomised study. World J Urol (2014) 0.78
Transfection of poly(I:C) can induce reactive oxygen species-triggered apoptosis and interferon-β-mediated growth arrest in human renal cell carcinoma cells via innate adjuvant receptors and the 2-5A system. Mol Cancer (2014) 0.78
[Distribution of elastic fiber on prostate]. Hinyokika Kiyo (2008) 0.78
Survey on lower urinary tract symptoms and sleep disorders in patients treated at urology departments. Nat Sci Sleep (2013) 0.78
Long-term outcome of kidney transplant using non-heart-beating donor: multicenter analysis of factors affecting graft survival. Clin Transplant (2003) 0.78
Effects of the Rho kinase inhibitor, hydroxyfasudil, on bladder dysfunction and inflammation in rats with HCl-induced cystitis. Int J Urol (2013) 0.77
Systemic transduction of p16INK4A antitumor peptide inhibits the growth of MBT-2 mouse bladder tumor cell line grafts. Int J Oncol (2012) 0.77
Clinical outcome of incidentally discovered small renal cell carcinoma after delayed surgery. Cancer Manag Res (2013) 0.77
Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy. Int J Urol (2013) 0.77
Changes in smooth muscle cell phenotype and contractile function following ischemia-reperfusion injury in the rat urinary bladder. Hinyokika Kiyo (2008) 0.77
A new molecular targeted therapeutic approach for renal cell carcinoma with a p16 functional peptide using a novel transporter system. Oncol Rep (2011) 0.77
Conditional PTEN-deficient mice as a prostate cancer chemoprevention model. Asian Pac J Cancer Prev (2015) 0.76
Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum. Int J Urol (2014) 0.76
[Penile metastasis from esophageal cancer: a case report]. Hinyokika Kiyo (2013) 0.76
Favorable outcome in elderly Asian patients with metastatic renal cell carcinoma treated with everolimus: the Osaka Urologic Oncology Group. Asian Pac J Cancer Prev (2014) 0.76
[A case of retrovesical leiomyoma]. Hinyokika Kiyo (2004) 0.76
Expression of the long-chain fatty acid receptor GPR120 in the gonadotropes of the mouse anterior pituitary gland. Histochem Cell Biol (2014) 0.76
Procalcitonin as a useful marker to decide upon intervention for urinary tract infection. Infect Drug Resist (2013) 0.75
Overall survival and final efficacy and safety results from a Japanese phase II study of axitinib in cytokine-refractory metastatic renal cell carcinoma. Cancer Sci (2014) 0.75
Clinical Outcome of Small Renal Cell Carcinoma after Delayed Surgery versus Immediate Surgery. J Cancer (2013) 0.75
[Effects of deep brain stimulation on urodynamic findings in patients with Parkinson's disease]. Hinyokika Kiyo (2007) 0.75
The efficacy of EBER in situ hybridization (ISH) stain in PTLD (malignant diffuse large B-cell lymphoma) about 4 years after ABO-incompatible kidney transplantation: a case report. Int J Clin Exp Pathol (2012) 0.75
Editorial comment from Dr Ishii to recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents. Int J Urol (2012) 0.75
[Left renal pelvic tumor 32 years after calyco-ileo-vesiconeostomy]. Hinyokika Kiyo (2006) 0.75
[Prostate cancer in a young adult : a case report]. Hinyokika Kiyo (2011) 0.75
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis. World J Urol (2014) 0.75
Bladder leiomyosarcoma in a boy. Int Urol Nephrol (2006) 0.75
[Sequential therapy for castration-resistant prostate cancer]. Nihon Rinsho (2016) 0.75
Prostate cancer immunotherapy: where are we and where are we going? Curr Opin Urol (2017) 0.75
[Pregnancy in chronic dialysis and after renal transplantation]. Hinyokika Kiyo (2006) 0.75
[Immunotherapy]. Nihon Rinsho (2016) 0.75
Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma. Int J Clin Oncol (2014) 0.75
Venous abnormalities incidentally accompanied by renal tumors. Urol Int (2004) 0.75
[Evaluation of the management of blunt renal trauma and indication for surgery]. Nihon Hinyokika Gakkai Zasshi (2002) 0.75
Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: sub-analysis of the multi-institutional national database of the Japanese Urological Association. Jpn J Clin Oncol (2016) 0.75
Matrix metalloproteinase levels in peritoneal effluents were increased in a patient with appendicitis undergoing continuous ambulatory peritoneal dialysis. Clin Exp Nephrol (2011) 0.75